Role of angiotensin II type 1 receptor in cerebral aneurysm formation in rats

International Journal of Molecular Medicine

Volumn 24, Issue 3, 2009, Pages 353-359

  Aoki, Tomohiro ^a   Nishimura, Masaki ^a   Kataoka, Hiroharu ^a   Ishibashi, Ryota ^a   Miyake, Takashi ^b   Takagi, Yasushi ^a   Morishita, Ryuichi ^b   Hashimoto, Nobuo ^a  

^a KYOTO UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin II type 1 receptor; Angiotensin receptor blocker; Animal model; Cerebral aneurysm; Valsartan

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; GELATINASE A; GELATINASE B; MESSENGER RNA; VALSARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; DRUG DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; TETRAZOLE DERIVATIVE; VALINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY WALL; ARTICLE; BRAIN ARTERY ANEURYSM; CELL COUNT; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; GENE EXPRESSION; MACROPHAGE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; UPREGULATION; ANIMAL; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; INTRACRANIAL ANEURYSM; METABOLISM; PATHOLOGY;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; CHEMOKINE CCL2; GENE EXPRESSION REGULATION, ENZYMOLOGIC; INTRACRANIAL ANEURYSM; MACROPHAGES; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NF-KAPPA B; RATS; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RNA, MESSENGER; TETRAZOLES; VALINE;

EID: 70349571939     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000239     Document Type: Article

References (32)

1. Ayabe N, Babaev VR, Tang Y, Tanizawa T, Fogo AB, Linton MF, Ichikawa I, Fazio S and Kon V: Transiently heightened angiotensin II has distinct effects on atherosclerosis and aneurysm formation in hyperlipidemic mice. Atherosclerosis 184: 312-321, 2006.
2. Daugherty A, Manning MW and Cassis LA: Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 105: 1605-1612, 2000.
3. Daugherty A, Rateri DL and Cassis LA: Role of the reninangiotensin system in the development of abdominal aortic aneurysms in animals and humans. Ann NY Acad Sci 1085: 82-91, 2006.
4. Iwai M, Chen R, Li Z, Shiuchi T, Suzuki J, Ide A, Tsuda M, Okumura M, Min LJ, Mogi M and Horiuchi M: Deletion of angiotensin II type 2 receptor exaggerated atherosclerosis in apolipoprotein E-null mice. Circulation 112: 1636-1643, 2005.
5. Liao S, Miralles M, Kelley BJ, Curci JA, Borhani M and Thompson RW: Suppression of experimental abdominal aortic aneurysms in the rat by treatment with angiotensin-converting enzyme inhibitors. J Vasc Surg 33: 1057-1064, 2001.
6. Nagai N, Oike Y, Izumi-Nagai K, Urano T, Kubota Y, Noda K, Ozawa Y, Inoue M, Tsubota K, Suda T and Ishida S: Angiotensin II type 1 receptor-mediated inflammation is required for choroidal neovascularization. Arterioscler Thromb Vasc Biol 26: 2252-2259, 2006.
7. Nishimoto M, Takai S, Fukumoto H, Tsunemi K, Yuda A, Sawada Y, Yamada M, Jin D, Sakaguchi M, Nishimoto Y, Sasaki S and Miyazaki M: Increased local angiotensin II formation in aneurysmal aorta. Life Sci 71: 2195-2205, 2002.
8. Wu L, Iwai M, Nakagami H, Li Z, Chen R, Suzuki J, Akishita M, de Gasparo M and Horiuchi M: Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury. Circulation 104: 2716-2721, 2001.
9. Yoshiyama M, Omura T, Takeuchi K, Kim S, Shimada K, Yamagishi H, Teragaki M, Akioka K, Iwao H and Yoshikawa J: Angiotensin blockade inhibits increased JNKs, AP-1 and NF-κB DNA-binding activities in myocardial infarcted rats. J Mol Cell Cardiol 33: 799-810, 2001.
10. El Bekay R, Alvarez M, Monteseirin J, Alba G, Chacon P, Vega A, Martin-Nieto J, Jimenez J, Pintado E, Bedoya FJ and Sobrino F: Oxidative stress is a critical mediator of the angiotensin II signal in human neutrophils: involvement of mitogen-activated protein kinase, calcineurin, and the transcription factor NF-κB. Blood 102: 662-671, 2003.
11. Nagai N, Izumi-Nagai K, Oike Y, Koto T, Satofuka S, Ozawa Y, Yamashiro K, Inoue M, Tsubota K, Umezawa K and Ishida S: Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway. Invest Ophthalmol Vis Sci 48: 4342-4350, 2007.
12. Lee FT, Cao Z, Long DM, Panagiotopoulos S, Jerums G, Cooper ME and Forbes JM: Interactions between angiotensin II and NF-κB-dependent pathways in modulating macrophage infiltration in experimental diabetic nephropathy. J Am Soc Nephrol 15: 2139-2151, 2004.
13. Pueyo ME, Arnal JF, Rami J and Michel JB: Angiotensin II stimulates the production of NO and peroxynitrite in endothelial cells. Am J Physiol 274: C214-C220, 1998.
14. Daugherty A and Cassis L: Angiotensin II and abdominal aortic aneurysms. Curr Hypertens Rep 6: 442-446, 2004.
15. Nishijo N, Sugiyama F, Kimoto K, Taniguchi K, Murakami K, Suzuki S, Fukamizu A and Yagami K: Salt-sensitive aortic aneurysm and rupture in hypertensive transgenic mice that overproduce angiotensin II. Lab Invest 78: 1059-1066, 1998.
16. Ohkuma H, Suzuki S, Fujita S and Nakamura W: Role of a decreased expression of the local renin-angiotensin system in the etiology of cerebral aneurysms. Circulation 108: 785-787, 2003.
17. Aoki T, Kataoka H, Shimamura M, Nakagami H, Wakayama K, Moriwaki T, Ishibashi R, Nozaki K, Morishita R and Hashimoto N: NF-κB is a key mediator of cerebral aneurysm formation. Circulation 116: 2830-2840, 2007.
18. Nagata I, Handa H, Hashimoto N and Hazama F: Experimentally induced cerebral aneurysms in rats: Part VI. Hypertension. Surg Neurol 14: 477-479, 1980.
19. Fujiwara Y, Shiraya S, Miyake T, Yamakawa S, Aoki M, Makino H, Nishimura M and Morishita R: Inhibition of experimental aortic abdominal aneurysm in a rat model by angiotensin receptor blocker, valsartan. Int J Mol Med 22: 703-708, 2008.
20. van Gijn J, Kerr RS and Rinkel GJ: Subarachnoid hemorrhage. Lancet 369: 306-318, 2007.
21. Feigin VL and Findlay M: Advances in subarachnoid hemorrhage. Stroke 37: 305-308, 2006.
22. Wermer MJ, Kool H, Albrecht KW and Rinkel GJ: Subarachnoid hemorrhage treated with clipping: long-term effects on employment, relationships, personality, and mood. Neurosurgery 60: 91-97, 2007.
23. Wiebers DO, Whisnant JP, Huston J III, Meissner I, Brown RD Jr, Piepgras DG, Forbes GS, Thielen K, Nichols D, O'Fallon WM, Peacock J, Jaeger L, Kassell NF, Kongable-Beckman GL and Torner JC: Unruptured intracranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatment. Lancet 362: 103-110, 2003.
24. Hashimoto N, Handa H and Hazama F: Experimentally induced cerebral aneurysms in rats. Surg Neurol 10: 3-8, 1978.
25. Aoki T, Kataoka H, Morimoto M, Nozaki K and Hashimoto N: Macrophage-derived matrix metalloproteinase-2 and -9 promote the progression of cerebral aneurysms in rats. Stroke 38: 162-169, 2007.
26. Hashimoto N, Handa H and Hazama F: Experimentally induced cerebral aneurysms in rats: Part III. Pathology. Surg Neurol 11: 299-304, 1979.
27. Aoki T, Moriwaki T, Takagi Y, Kataoka H, Nozaki K and Hashimoto N: The efficacy of apolipoprotein E deficiency in experimental cerebral aneurysm formation. Int J Mol Med 21: 453-459, 2008.
28. Wilson WR, Anderton M, Schwalbe EC, Jones JL, Furness PN, Bell PR and Thompson MM: Matrix metalloproteinase-8 and -9 are increased at the site of abdominal aortic aneurysm rupture. Circulation 113: 438-445, 2006.
29. Jones JA, Barbour JR, Lowry AS, Bouges S, Beck C, McClister DM Jr, Mukherjee R and Ikonomidis JS: Spatiotemporal expression and localization of matrix metalloproteinase- 9 in a murine model of thoracic aortic aneurysm. J Vasc Surg 44: 1314-1321, 2006.
30. Daugherty A, Manning MW and Cassis LA: Antagonism of AT2 receptors augments angiotensin II-induced abdominal aortic aneurysms and atherosclerosis. Br J Pharmacol 134: 865-870, 2001.
31. Yamamoto S, Hayashi N, Kometani M, Nakao K and Inukai T: Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 1st communication: antihypertensive effects of valsartan in hypertensive models. Arzneimittelforschung 47: 604-612, 1997.
32. Thurmann PA: Valsartan: a novel angiotensin type 1 receptor antagonist. Expert Opin Pharmacother 1: 337-350, 2000.